Mineralys Therapeutics, Inc. Common Stock (MLYS NASDAQ) stock market data APIs
$32.3445
0.12(0.4%)
as of January 29, 2026
Try our APIs with
free plan!
Mineralys Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Prev. Close
32.3445
Open
32.4645
High
32.4913
Low
31.654
52 wk Range
8.241-47.65
Market Cap
2 540 M
Shares Outstanding
79 140 K
EPS
-0.52
Beta
0.495
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Mineralys Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mineralys Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Mineralys Therapeutics, Inc. Common Stock Fundamental Data
Mineralys Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -184 030 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Mineralys Therapeutics, Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-11-11
- EPS/Forecast: -0.64
Get Mineralys Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mineralys Therapeutics, Inc. Common Stock News
New
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
For Immediate Releases Chicago, IL – December 26, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news ...
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector picked up in the past couple of months. This can be attributed to improved poli...
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
Key Points New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous...
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
Key Points New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previou...
Get Mineralys Therapeutics, Inc. Common Stock fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
